Of mice and men: More neurobiology in dementia

Current Opinion in Psychiatry

Volumn 19, Issue 6, 2006, Pages 555-563

  Codita, Alina ^a   Winblad, Bengt ^a   Mohammed, Abdul H ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LINNAEUS UNIVERSITY   (Sweden)

Author keywords

Alzheimer disease; apoE; APP; Tau; Transgenic mice

Indexed keywords

AMYLOID; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; PRESENILIN 1; TAU PROTEIN;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM; DEMENTIA; ELECTROPHYSIOLOGY; GENE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NEUROBIOLOGY; NONHUMAN; NULL ALLELE; PROTEIN EXPRESSION; REVIEW; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; BIOMEDICAL RESEARCH; DEMENTIA; DISEASE MODELS, ANIMAL; HUMANS; MACACA MULATTA; MICE; MICE, TRANSGENIC; NEUROBIOLOGY;

EID: 33749463108     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yco.0000245757.06374.6a     Document Type: Review

References (130)

1. Poirier J, Davignon J, Bouthillier D, et al. Apolipoprotein E polymorphism and Alzheimer disease. Lancet 1993; 342:697-699.
2. Saunders A, Strittmatter W, Schmechel D, et al. Association of apoliprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43:1467-1472.
3. Roses A. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev Med 1996; 47:387-400.
4. Blacker D, Wilcox M, Laird N, et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet 1998; 19:357-360.
5. Dodel R, Du Y, Bales K, et al. Alpha-2 macroglobulin and the risk of Alzheimer's disease. Neurology 2000; 54:438-442.
6. Lehmann DJ, Cortina-Borja M, Warden DR, et al. Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease. Am J Epidemiol 2005; 162:305-317. After analysing data from 6037 patients with Alzheimer disease and 12 099 controls, the authors conclude that angiotensin I-converting enzyme (ACE) indel is a marker for the risk of Alzheimer disease, probably in linkage disequilibrium with the true risk polymorphism.
7. Campion D, Dumanchin C, Hannequin D, et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity and mutation spectrum. Am J Hum Genet 1999; 65:664-670.
8. Goate A, Chartier-Harlin M, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor gene with familial Alzheimer's disease. Nature 1991; 349:704-706.
9. Sherrington R, Rogaev E, Liang Y, et al. Cloning a gene bearing missense mutations in early-onset familial Alzheimer disease. Nature 1995; 375:754-760.
10. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer disease locus. Science 1995; 269:973-977.
11. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991; 82:239-259.
12. Fewster P, Griffin-Brooks S, MacGregor J, et al. A topographical pathway by which histopathological lesions disseminate through the brain of patients with Alzheimer disease. Dementia 1991; 2:121-132.
13. Giannakopoulos P, Hof P, Bouras C. Selective vulnerability of neocortical association areas in Alzheimer's disease. Microsc Res Tech 1998; 43:16-23.
14. Davies P, Maloney J. Selective loss of central cholinergic neurons in Alzheimer disease. Lancet 1976; 2:1403.
15. Muir J. Acetylcholine, aging, and Alzheimer disease. Pharmacol Biochem Behav 1997; 56:687-696.
16. Pratico D, Trojanowski J. Inflamatory hypotheses: novel mechanisms of Alzheimer's neurodegeneration and new therapeutic targets? Neurobiol Aging 2000; 21:441-445.
17. Schliebs R. Basal forebrain cholinergic dysfunction in Alzheimer's disease interrelationship with beta-amyloid, inflammation and neurotrophin signaling. Neurochem Res 2005; 30:895-908. The author reviews the complex interrelationship between cholinergic neurotransmission, APP metabolism and -amyloid-induced production of proinflammatory cytokines hypothesizing that an age-related disturbance of the homeostatic interaction between cholinergic function and APP metabolism plays a major role in the genesis of SAD.
18. de la Torre J. Critical threshold cerebral hypoperfusion causes Alzheimer disease? Acta Neuropathol (Berl) 1999; 98:1-8.
19. Farkas E, Luiten P. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol 2001; 64:575-611.
20. Brun A, Liu X, Erikson C. Synapse loss and gliosis in the molecular layer of the cerebral cortex in Alzheimer's disease and frontal lobe degeneration. Neurodegeneration 1995; 4:171-177.
21. Gomez-Isla T, Hollister R, West H, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997; 41:17-24.
22. Jellinger K, Stadelmann C. Problems of cell death in neurodegeneration and Alzheimer's disease. J Alzheimers Dis 2001; 3:31-40.
23. Handler M, Yang X, Shen J. Presenilin-1 regulates neuronal differentiation during neurogenesis. Development 2000; 127:2593-2606.
24. Selkoe D, Kopan R. Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci 2003; 26:565-597.
25. Jin K, Peel A, Mao X, et al. Increased hippocampal neurogenesis in Alzheimer's disease. Proc Natl Acad Sci USA 2004; 101:343-347.
26. Chartier-Harlin M, Crawford F, Houlden H, et al. Early-onset Alzheimer disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 1991; 353:844-846.
27. Haass C, Lemere C, Capell A, et al. The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat Med 1995; 1:1291-1296.
28. Citron M, Westaway D, Xia W, et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 1997; 3:67-72.
29. Kivipelto M, Ngandu T, Fratiglioni L, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 2005; 62:1556-1560. The authors investigated how the clustering of vascular risk factors affects the risk of developing Alzheimer disease.
30. Schmechel D, Saunders A, Strittmatter W, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993; 90:9649-9653.
31. Lambert J, Araria-Goumidi L, Myllykangas L, et al. Contribution of APOE promoter polymorphysms to Alzheimer's disease risk. Neurology 2002; 59:59-66.
32. Saunders A, Bertram L, Mullin K, et al. Genetic association of Alzheimer disease with multiple polymorphisms in alpha-2-macroglobulin. Hum Mol Genet 2003; 12:2765-2776.
33. Licastro F, Pedrini S, Ferri C, et al. Gene polymorphism affecting alpha 1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk. Ann Neurol 2000; 48:388-391.
34. Licastro F, Grimaldi LM, Bonafe M, et al. Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the cytokine in blood and brain. Neurobiol Aging 2003; 24:921-926.
35. Zhang Y, Hayes A, Pritchard A, et al. Interleukin-6 promoter polymorphism: risk and pathology of Alzheimer's disease. Neurosci Lett 2004; 362:99-102.
36. Hardy J, Higgins G. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992; 256:184-185.
37. Hardy J, Selkoe D. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297:353-356.
38. Kimberly W, LaVoie M, Ostaszewski B, et al. Gamma secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1 and Pen-2. Proc Natl Acad Sci USA 2003; 100:6382-6387.
39. Takasugi N, Tomita T, Hayashi I, et al. The role of presenilin cofactors in the gamma-secretase complex. Nature 2003; 422:438-441.
40. Suh Y, Checler F. Amyloid precursor protein, presenilins and alpha synuclein: molecular pathogenesis and pharmacological applications in Alzheimer disease. Pharmacol Rev 2002; 54:469-525.
41. Crowther R, Wischik C. Image reconstruction of the Alzheimer paired helical filament. Embo J 1985; 4:3661-3665.
42. Goedert M, Wischik CM, Crowther RA, et al. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci USA 1988; 85:4051-4055.
43. Gotz J, Schild A, Hoerndli F, Pennanen L. Amyloid induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue culture models. Int J Dev Neurosci 2004; 22:453-465.
44. Delacourte A, Buee L. Animal models of Alzheimer's disease: a road full of pitfalls. Psychol Neuropsychiatr Vieil 2005; 3:261-270.
45. Richardson A. Animal models of aging. Aging (Milano) 1997; 9:439-441.
46. Price D, Sisodia S. Cellular and molecular biology of Alzheimer's disease and animal models. Annu Rev Med 1994; 45:435-446.
47. Hutton M, Lendon C, Rizzu P, et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393:702-705.
48. Poorkaj P, Bird T, Wijsman E, et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol 1998; 43:815-825.
49. Spillantini M, Murrell J, Goedert M, et al. Mutation in tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA 1998; 95:7737-7741.
50. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717 beta-amyloid precursor protein. Nature 1995; 373:523-527.
51. Redwine J, Kosofsky B, Jacobs R, et al. Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: a magnetic resonance microscopy and stereologic analysis. Proc Natl Acad Sci USA 2003; 100:1381-1386.
52. Wu CC, Chawla F, Games D, et al. Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: digital morphometric analyses. Proc Natl Acad Sci USA 2004; 101:7141-7146.
53. Irizarry M, Soriano F, McNamara M, et al. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mice. J Neurosci 1997; 17:7053-7059.
54. Masliah E, Sisk A, Mallory M, Games D. Neurofibrillary pathology induced in transgenic mice overexpressing V717F beta-amyloid precursor protein. J Neuropathol Exp Neurol 2001; 60:357-368.
55. Diez M, Koistinaho J, Kahn K, et al. Neuropeptides in hippocampus and cortex in transgenic mice overexpressing V717F beta-amyloid precursor protein-initial observations. Neuroscience 2000; 100:259-286.
56. Donovan M, Yazdani U, Norris R, et al. Decreased adult hippocampal neurogenesis in the PDAPP mouse model of Alzheimer's disease. J Comp Neurol 2006; 495:70-83. While some studies link Alzheimer disease to increased neurogenesis, in the PDAPP the primary characteristic is decreased neurogenesis. This feature might contribute to the cognitive decline and thus could be used as a supplementary means to evaluate Alzheimer disease therapies.
57. Larson J, Lynch G, Games D, Seubert P. Alterations in synaptic transmission and long-term potentiation in hippocampal slice from young and aged PDAPP mice. Brain Res 1999; 840:23-35.
58. Huitron-Resendiz S, Sanchez-Alavez M, Gallegos R, et al. Age-independent and age-related deficits in visuospatial learning, sleep-wake states, thermoregulation and motor activity in the PDAPP mice. Brain Res 2002; 928:126-137.
59. Chen G, Chen K, Knox J, et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 2000; 408:975-979.
60. Hartman R, Izumi Y, Bales K, et al. Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J Neurosci 2005; 25:6213-6220. PDAPP mice, on a pure C57BL/6 background, tested on a 5-week water maze protocol, have early learning impairments and exhibit greater cognitive deterioration with age than their WT littermates. The authors also show that after systemic treatment for several weeks with an anti-Abeta antibody, the performance of animals with high Abeta burden is improved.
61. Dodart J, Mathis C, Bales K, Paul S. Does my mouse have Alzheimer's disease? Genes Brain Behav 2002; 1:142-155.
62. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996; 274:99-102.
63. Smith MA, Hirai K, Hsiao K, et al. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 1998; 70:2212-2215.
64. Yao Y, Chinnici C, Tang H, et al. Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis. J Neuroinflammation 2004; 1:21, doi: 10.1186/1742-2094-1-21.
65. Paris D, Patel N, DelleDonne A, et al. Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neurosci Lett 2004; 366:80-85.
66. Jacobsen J, Wu C, Redwine J, et al. Early-onset behavioural and synaptic deficits in a mouse model of Alzheimer disease. Proc Natl Acad Sci USA 2006; 103:5161-5166. Morphological, functional and behavioural changes in the Tg 2576 line are consistent with a compromised perforant path input from the enthorhinal cortex to the dentate gyrus.
67. Middei S, Geracitano R, Caprioli A, et al. Preserved fronto-striatal plasticity and enhanced procedural learning in a transgenic mouse model of Alzheimer's disease overexpressing mutant hAPPSwe. Learn Mem 2004; 11:447-452.
68. Sturchler-Pierrat C, Abramowski D, Duke M, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer-like pathology. Proc Natl Acad Sci USA 1997; 94:13287-13292.
69. Moechars D, Dewachter I, Lorent K, et al. Early phenotipic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 1999; 274:6483-6492.
70. Hwang D, Cho J, Lee S, et al. Aberrant expressions of pathogenic phenotype in Alzheimer's disease transgenic mice carrying NSE-controlled APPSwe. Exp Neurol 2004; 186:20-32.
71. Van Dam D, Vloeberghs E, Abramowski D, et al. APP 23 mice as a model of Alzheimer's disease example of transgenic approach to modeling a CNS disorder. CNS Spectr 2005; 10:207-222.
72. Calhoun M, Wiederhold K, Abramowski D, et al. Neuron loss in APP transgenic mice. Nature 1998; 395:755-756.
73. Winkler D, Bondolfi L, Herzig M, et al. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci 2001; 21:1619-1627.
74. Lahiri D, Ge Y, Maloney B, et al. Characterization of two APP gene promoter polymorphisms that appear to influence the risk of late on-set Alzheimer disease. Neurobiol Aging 2005; 26:1329-1341. Further characterization of regulatory mechanisms of Alzheimer disease-related genes, like the APP gene promoter investigated by the authors, could lead to deciphering the mechanisms underlying SAD cases.
75. Miller R, Austad S, Burke D, et al. Exotic mice as models for aging research: polemic and prospectus. Neurobiol aging 1999; 20:217-231.
76. Hsiao K. Transgenic mice expressing Alzheimer amyloid precursor proteins. Exp Gerontol 1998; 33:883-889.
77. Wolfer DP, Lipp HP. Dissecting the behaviour of transgenic mice: is it the mutation the genetic background, or the environment? Exp Physiol 2000; 85:627-634.
78. Janus C, Pearson J, McLaurin J, et al. A beta peptide immunisation reduces behavioural impairment and plaques in a model of Alzheimer disease. Nature 2000; 408:979-982.
79. Chishti M, Yang D, Janus C, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 2001; 276:21562-21570.
80. Mucke L, Masliah E, Yu G, et al. High-level neuronal expression of Abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 2000; 20:4050-4058.
81. Hsia A, Masliah E, McConlogue L, et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 1999; 96:3228-3233.
82. McLean C, Cherny R, Fraser F, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer disease. Ann Neurol 1999; 46:860-866.
83. Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. Jama 2000; 283:1571-1577.
84. Walsh D, Klyubin I, Fadeeva J, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416:535-539.
85. Deshpande A, Mina E, Glabe C, Busciglio J. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci 2006; 26:6011-6018. Aβ oligomers, Aβ-derived diffusible ligands and fibrillar Ab are shown to act in a different temporal manner and by activating distinct pathways in human cortical neurons.
86. Lesne S, Koh M, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006; 440:352-357. A specific soluble amyloid beta assembly of 56-kDa, purified from the brains of impaired Tg 2576 and demonstrated to cause memory deficits in young rats is proposed as a determinant of cognitive deficits in Alzheimer disease.
87. Lord A, Kalimo H, Eckman C, et al. The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiol Aging 2006; 27:67-77. This is an interesting new model for Abeta aggregation. Further studies using the tg-APPArc/Swe mice could result in linking intraneuronal Abeta and tau pathology and increase the understanding of early stages of Alzheimer disease.
88. Nilsberth C, Westlind-Danielsson A, Eckman C, et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 2001; 4:887-893.
89. Duff K, Eckman C, Zehr C, et al. Increased amyloid-beta 42(43) in brains of mice expressing mutant presenilin 1. Nature 1996; 383:710-713.
90. Qian S, Jiang P, Guan X, et al. Mutant human presenilin 1 protects presenilin null mouse against embryonic lethality and elevates Abeta 1-42/43 expression. Neuron 1998; 20:611-617.
91. Barrow P, Empson R, Gladwell S, et al. Functional phenotype in transgenic mice expressing mutant presenilin-1. Neurobiol Dis 2000; 7:119-126.
92. Lalonde R, Strazielle C. PS1 knockin mice with the Japanese I213T mutation: effects on exploratory activity, motor coordination, and spatial learning. Behav Brain Res 2005; 162:182-190. SHIRPA primary screen and a large battery of elaborated tests were used in the presented study in order to characterize the exploratory behaviour, motor coordination and spatial learning of the PS1/I213T KI mice.
93. Hwang DY, Chae KR, Kang TS, et al. Alterations in behavior, amyloid beta-42, caspase-3, and Cox-2 in mutant PS2 transgenic mouse model of Alzheimer's disease. FASEB J 2002; 16:805-813.
94. Wirths O, Multhaup G, Czech C, et al. Intraneuronal APP/A beta trafficking and plaque formation in beta-amyloid precursor and presenilin 1 transgenic mice. Brain Pathol 2002; 12:275-286.
95. Blanchard V, Moussaoui S, Czech C, et al. Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic mice. Exp Neurol 2003; 184:247-263.
96. Casas C, Sergeant N, Itier J, et al. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta 42 accumulation in a novel Alzheimer transgenic model. Am J Pathol 2004; 165:1289-1300.
97. Dickson D. Building a more perfect beast: APP transgenic mice with neuronal loss. Am J Pathol 2004; 164:1143-1146.
98. Reaume A, Howland D, Trusko S, et al. Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a 'humanized' Abeta sequence. J Biol Chem 1996; 271:23380-23388.
99. Kohler C, Ebert U, Baumann K, Schroder H. Alzheimer's disease-like neuropathology of gene targeted APP-SLxPS1mut mice expressing the amyloid precursor protein at endogenous levels. Neurobiol Dis 2005; 20:528-540.
100. Gotz J, Probst A, Spillantini MG, et al. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human tau. EMBO J 1995; 14:1304-1313.
101. Lewis J, McGowan E, Rockwood J, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 2000; 25:402-405.
102. Gotz J, Chen F, Barmettler R, Nitsch R. Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 2001; 276:529-534.
103. Higuchi M, Ishihara T, Zhang B, et al. Transgenic mouse model of tauopathies with glial pathology and nervous system degeneration. Neuron 2002; 35:433-446.
104. Allen B, Ingram E, Takao M, et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci 2002; 22:9340-9351.
105. Gotz J, Chen F, van Dorpe. Nitsch RM. Formation of neurofibrillary tangles in P301L transgenic mice induced by Abeta 42 fibrils. Science 2001; 293:1491-1495.
106. Gotz J, Streffer J, David D, et al. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behaviour and therapy. Mol Psychiatry 2004; 9:664-683.
107. Wirths O, Weis J, Szczygielski J, et al. Axonopathy in an APP/PS1 transgenic mouse model of Alzheimer disease. Acta Neuropathol (Berl) 2006; 111:312-319. The study demonstrates that high Ab intracellular levels lead to the formation of axonal spheroids and myelin ovoids, affecting both descending and ascending axonal tracts, in the white matter of an APP/PS1 tg mouse model of Alzheimer disease.
108. Gotz J, Ittner L, Kins S. Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease. J Neurochem 2006; 98:993-1006. The authors review the evidence attesting the important and early role of impaired axonal transport in Alzheimer disease.
109. Oddo S, Caccamo A, Shepherd J, et al. Triple transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003; 39:409-421.
110. ••].
111. ••], constitutes a step forward in clarifying the relationship between different Abeta pools and their relation to tau pathology.
112. Oddo S, Billings L, Kesslak J, et al. Abeta immunotherapy leads to clearance of early, but not late hyperphosphorylated tau aggregates via proteasome. Neuron 2004; 43:321-332.
113. Nagasaka Y, Dillner K, Ebise H, et al. A unique gene expression signature discriminates familial Alzheimer's disease mutation carriers from their wildtype siblings. Proc Natl Acad Sci USA 2005; 102:14854-14859. The authors provide evidence for significantly different gene expression levels in FAD mutation carriers and their wild-type siblings, which are present before the onset of clinical symptoms and can be detected in fibroblasts, a seemingly disease-unrelated tissue.
114. Corder E, Saunders A, Strittmatter W, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261:921-923.
115. Bales K, Dodart J, DeMattos R, et al. Apolipoprotein E, amyloid and Alzheimer disease. Mol Interv 2002; 2:363-375; 339.
116. Zhang S, Reddick R, Piedrahita J, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258:468-471.
117. Plump A, Breslow J. Apolipoprotein E and the apolipoprotein E-deficient mouse. Annu Rev Nutr 1995; 15:495-518.
118. Holtzman D, Fagan A, Mackey B, et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol 2000; 47:739-747.
119. Huang Y. Apolipoprotein E and Alzheimer disease. Neurology 2006; 66:S79-S85.
120. Cedazo-Minguez A, Cowburn R. Apolipoprotein E: a major piece in the Alzheimer's disease puzzle. J Cell Mol Med 2001; 5:254-266.
121. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400:173-177.
122. Lemere C, Maier M, Jiang L, et al. Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys and humans. Rejuvenation Res 2006; 9:77-84. In this review the authors discuss important steps made on the road to finding a safe and effective Abeta vaccine.
123. Orgogozo J, Gilman S, Dartigues J, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta-42 immunization. Neurology 2003; 61:46-54.
124. Gandy S, DeMattos R, Lemere C, et al. Alzheimer Abeta vaccination of rhesus monkeys (Macaca mulatta). Alzheimer Dis Assoc Disord 2004; 18:44-46.
125. Bons N, Rieger F, Prudhomme D, et al. Microcebus murinus: a useful primate model for human cerebral aging and Alzheimer's disease? Genes Brain Behav 2006; 5:120-130.
126. Podlisny M, Tolan D, Selkoe D. Homology of the amyloid beta precursor in monkey and human supports a primate model for beta amyloidosis in Alzheimer's disease. Am J Pathol 1991; 138:1423-1435.
127. Furlan R, Brambilla E, Sanvito F, et al. Vaccination with amyloid-beta peptide induces autoimmune enchephalomyelitis in C57/BL6 mice. Brain 2003; 126:285-291.
128. Leighty R, Nilsson L, Potter H, et al. Use of multimetric statistical analysis to characterize and discriminate between the performance of four Alzheimer's transgenic mouse lines differing in Abeta deposition. Behav Brain Res 2004; 153:107-121.
129. Lazarov O, Robinson J, Tang Y, et al. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 2005; 120:701-713. The study highlights the efficacy of environmental enrichment in reducing levels of brain Abeta and amyloid depositions in transgenic mice. The authors also present data showing that physical exercise lowers brain Abeta levels. These findings are intriguing in light of epidemiological data linking the risk for development of dementia to environmental factors such as education and life style.
130. Mohammed A, Zhu S, Darmopil S, et al. Environmental enrichment and the brain. Prog Brain Res 2002; 138:109-133.